Brief: Biohaven Says FDA Extends PDUFA Date Of Biohaven's Troriluzole NDA For Rare Disease Spinocerebellar Ataxia
14/05/2025 23:45
May 14 (Reuters) - Biohaven Ltd BHVN.N: FDA EXTENDS PDUFA DATE OF BIOHAVEN'S TRORILUZOLE NDA FOR RARE DISEASE SPINOCEREBELLAR ATAXIA BIOHAVEN LTD - FDA'S DECISION REGARDING NDA IS NOW EXPECTED IN 4Q 2025. Source text: ID:nPn6YwSwKa Further company coverage: BHVN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean